DK3677266T3 - Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer - Google Patents
Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer Download PDFInfo
- Publication number
- DK3677266T3 DK3677266T3 DK18851555.5T DK18851555T DK3677266T3 DK 3677266 T3 DK3677266 T3 DK 3677266T3 DK 18851555 T DK18851555 T DK 18851555T DK 3677266 T3 DK3677266 T3 DK 3677266T3
- Authority
- DK
- Denmark
- Prior art keywords
- exon
- selective inhibitor
- mutant egfr
- egfr selective
- mutant
- Prior art date
Links
- 229940124639 Selective inhibitor Drugs 0.000 title 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 title 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 title 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2017168606 | 2017-09-01 | ||
| PCT/JP2018/032314 WO2019045036A1 (ja) | 2017-09-01 | 2018-08-31 | エクソン１８及び／又はエクソン２１変異型ｅｇｆｒ選択的阻害剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK3677266T3 true DK3677266T3 (da) | 2024-04-22 |
| DK3677266T5 DK3677266T5 (da) | 2024-08-26 |
Family
ID=65527547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK18851555.5T DK3677266T5 (da) | 2017-09-01 | 2018-08-31 | Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US11701359B2 (da) |
| EP (1) | EP3677266B1 (da) |
| JP (1) | JP7065103B2 (da) |
| KR (1) | KR102676530B1 (da) |
| CN (2) | CN111465397B (da) |
| AU (1) | AU2018325819B2 (da) |
| CA (2) | CA3224526A1 (da) |
| DK (1) | DK3677266T5 (da) |
| ES (1) | ES2972895T3 (da) |
| FI (1) | FI3677266T3 (da) |
| HU (1) | HUE066587T2 (da) |
| IL (1) | IL272929B2 (da) |
| JO (1) | JOP20200044A1 (da) |
| MX (1) | MX2020002296A (da) |
| MY (1) | MY199676A (da) |
| NZ (1) | NZ762195A (da) |
| PH (1) | PH12020500419A1 (da) |
| PL (1) | PL3677266T3 (da) |
| PT (1) | PT3677266T (da) |
| SG (1) | SG11202001861WA (da) |
| TW (1) | TWI838345B (da) |
| WO (1) | WO2019045036A1 (da) |
| ZA (1) | ZA202001445B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190073A1 (ar) | 2016-10-31 | 2019-04-07 | Taiho Pharmaceutical Co Ltd | مثبط انتقائي لمستقبل عامل نمو بشروي (egfr) لطافر إدخال exon 20 |
| CN111465397B (zh) | 2017-09-01 | 2023-10-13 | 大鹏药品工业株式会社 | 外显子18和/或外显子21突变型egfr的选择性抑制剂 |
| FI3902548T3 (fi) * | 2018-12-28 | 2025-07-17 | Taiho Pharmaceutical Co Ltd | Hoitoresistentin L718- ja/tai L792-mutaation omaavan EGFR:n inhibiittori käytettäväksi syövän hoitamisessa |
| US20230372346A1 (en) * | 2020-09-08 | 2023-11-23 | Cullinan Pearl Corp. | Treatment regimens for exon-20 insertion mutant egfr cancers |
| WO2022121967A1 (zh) * | 2020-12-09 | 2022-06-16 | 南京药石科技股份有限公司 | Egfr酪氨酸激酶抑制剂及其用途 |
| TW202309022A (zh) | 2021-04-13 | 2023-03-01 | 美商努法倫特公司 | 用於治療具egfr突變之癌症之胺基取代雜環 |
| CN115785107B (zh) * | 2022-12-15 | 2024-11-12 | 南京雷正医药科技有限公司 | 一种取代8,9-二氢嘧啶并[5,4-b]吲嗪类化合物、药物组合物及其用途 |
| TW202515577A (zh) * | 2023-06-27 | 2025-04-16 | 日商大鵬藥品工業股份有限公司 | 患有具有ｅｇｆｒ畸變的非小細胞肺癌之個體的治療方法 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW440562B (en) | 1994-05-20 | 2001-06-16 | Taiho Pharmaceutical Co Ltd | Condensed-indan derivative and pharmaceutically acceptable salts thereof |
| JP2008533172A (ja) | 2005-03-17 | 2008-08-21 | ノバルティス アクチエンゲゼルシャフト | チロシン／スレオニンキナーゼ阻害剤、特にＢ−ＲＡＦキナーゼ阻害剤としての、Ｎ−［３−（１−アミノ−５，６，７，８−テトラヒドロ−２，４，４ｂ−トリアザフルオレン−９−イル）−フェニル］ベンズアミド |
| DK1800675T3 (da) | 2005-12-23 | 2011-09-05 | Nutricia Nv | Sammensætninger omfattende polyumættede fedtsyrer, proteiner og mangan og/eller molybdæn og nucleosider/nucleotider til behandling af demens |
| EP2452940B1 (en) | 2009-07-10 | 2014-12-17 | Taiho Pharmaceutical Co., Ltd. | Azabicyclo compound and salt thereof |
| US7741330B1 (en) | 2009-10-12 | 2010-06-22 | Pharmacyclics, Inc. | Pyrazolo-pyrimidine inhibitors of Bruton's tyrosine kinase |
| US8912181B2 (en) | 2011-01-07 | 2014-12-16 | Taiho Pharmaceutical Co., Ltd. | Bicyclic compound or salt thereof |
| WO2013047813A1 (ja) | 2011-09-30 | 2013-04-04 | 大鵬薬品工業株式会社 | １，２，４－トリアジン－６－カルボキサミド誘導体 |
| TWI594986B (zh) | 2011-12-28 | 2017-08-11 | Taiho Pharmaceutical Co Ltd | Antineoplastic agent effect enhancer |
| TW201336847A (zh) | 2012-02-07 | 2013-09-16 | Taiho Pharmaceutical Co Ltd | 喹啉基吡咯并嘧啶化合物或其鹽 |
| MX351863B (es) | 2012-02-23 | 2017-10-30 | Taiho Pharmaceutical Co Ltd | Compuesto de anillo fusionado quinolilpirrolopirimidilo o sal del mismo. |
| WO2014129596A1 (ja) | 2013-02-22 | 2014-08-28 | 大鵬薬品工業株式会社 | 三環性化合物の製造方法及び当該製造方法により得ることができる三環性化合物 |
| CA2922077C (en) | 2013-08-22 | 2018-06-26 | Taiho Pharmaceutical Co., Ltd. | Quinoline-substituted compound |
| WO2015175632A1 (en) | 2014-05-13 | 2015-11-19 | Ariad Pharmaceuticals, Inc. | Heteroaryl compounds for kinase inhibition |
| PH12016502453B1 (en) | 2014-06-19 | 2022-11-23 | Takeda Pharmaceuticals Co | Heteroaryl compounds for kinase inhibition |
| JP6583614B2 (ja) | 2015-05-11 | 2019-10-02 | 大同特殊鋼株式会社 | アーク炉の電極折損防止装置 |
| CN111465397B (zh) | 2017-09-01 | 2023-10-13 | 大鹏药品工业株式会社 | 外显子18和/或外显子21突变型egfr的选择性抑制剂 |
-
2018
- 2018-08-31 CN CN201880064210.3A patent/CN111465397B/zh active Active
- 2018-08-31 HU HUE18851555A patent/HUE066587T2/hu unknown
- 2018-08-31 CN CN202310869220.7A patent/CN117159551A/zh active Pending
- 2018-08-31 FI FIEP18851555.5T patent/FI3677266T3/fi active
- 2018-08-31 WO PCT/JP2018/032314 patent/WO2019045036A1/ja not_active Ceased
- 2018-08-31 CA CA3224526A patent/CA3224526A1/en active Pending
- 2018-08-31 CA CA3074418A patent/CA3074418C/en active Active
- 2018-08-31 PL PL18851555.5T patent/PL3677266T3/pl unknown
- 2018-08-31 SG SG11202001861WA patent/SG11202001861WA/en unknown
- 2018-08-31 AU AU2018325819A patent/AU2018325819B2/en active Active
- 2018-08-31 KR KR1020207008984A patent/KR102676530B1/ko active Active
- 2018-08-31 US US16/642,969 patent/US11701359B2/en active Active
- 2018-08-31 DK DK18851555.5T patent/DK3677266T5/da active
- 2018-08-31 EP EP18851555.5A patent/EP3677266B1/en active Active
- 2018-08-31 MY MYPI2020001066A patent/MY199676A/en unknown
- 2018-08-31 MX MX2020002296A patent/MX2020002296A/es unknown
- 2018-08-31 NZ NZ762195A patent/NZ762195A/en unknown
- 2018-08-31 ES ES18851555T patent/ES2972895T3/es active Active
- 2018-08-31 TW TW107130585A patent/TWI838345B/zh active
- 2018-08-31 IL IL272929A patent/IL272929B2/en unknown
- 2018-08-31 JO JOP/2020/0044A patent/JOP20200044A1/ar unknown
- 2018-08-31 JP JP2019539655A patent/JP7065103B2/ja active Active
- 2018-08-31 PT PT188515555T patent/PT3677266T/pt unknown
-
2020
- 2020-03-02 PH PH12020500419A patent/PH12020500419A1/en unknown
- 2020-03-06 ZA ZA2020/01445A patent/ZA202001445B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL284748A (en) | Anti-cyberbullying systems and methods | |
| EP3659138C0 (en) | SELECTION SYSTEM AND METHOD | |
| LT3661921T (lt) | Selektyvūs nlrp3 inflamasomos inhibitoriai | |
| DK3677266T5 (da) | Exon-18- og/eller exon-21-mutant egfr-selektiv hæmmer | |
| EP3500671A4 (en) | SYSTEMS AND NEW ENZYMES CRISPR AND SYSTEMS | |
| IL259766A (en) | Relocalization systems and methods | |
| IL258437B (en) | Growing systems and methods | |
| HUE055233T2 (hu) | Az EGFR gátló és annak elkészítése és alkalmazása | |
| HUE054159T2 (hu) | HPK1 gátlók és azok alkalmazási módja | |
| EP3711001A4 (en) | AI-BASED COMPLIANCE AND PREFERENCE SYSTEM | |
| IL280863A (en) | Autotaxin inhibitors and uses thereof | |
| KR20180084972A (ko) | 조명 및 사운드 시스템 | |
| DK3610005T3 (da) | Peptidligase og anvendelse deraf | |
| EP3474972A4 (en) | AIR TREATMENT SYSTEMS AND METHODS | |
| DK3502253T3 (da) | Hidtil ukendte crispr-enzymer og -systemer | |
| DK3452463T3 (da) | Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf | |
| EP3572400C0 (en) | Ezh2 inhibitor and use thereof | |
| PL3265448T3 (pl) | Proleki riluzolu i ich zastosowanie | |
| IL282178A (en) | Products, uses & methods | |
| EP3551835A4 (en) | WELL HEAD SYSTEMS AND METHODS | |
| EP3420456A4 (en) | PLAYBACK PROTECTION SYSTEMS AND METHOD | |
| PL3341664T3 (pl) | Sposób obsługi urządzenia chłodniczego i urządzenie chłodnicze | |
| DK3368613T3 (da) | Matteringsmiddel og fremgangsmåde til fremstilling deraf | |
| HUE063120T2 (hu) | LRRC33-inhibitorok és alkalmazásuk | |
| EP3426242A4 (en) | ICARITINE AND ICARITINE DERIVATIVES |